Department of Diagnostic and Interventional Radiology and Neuroradiology, Augsburg University Hospital, Augsburg, Germany.
Institute of Mathematics, Augsburg University, Augsburg, Germany.
Cardiovasc Intervent Radiol. 2023 Mar;46(3):377-384. doi: 10.1007/s00270-023-03372-7. Epub 2023 Feb 16.
Intracranial rescue stent angioplasty is a bailout strategy for acute stroke patients in cases of unsuccessful endovascular thrombectomy due to underlying atherosclerotic stenosis. However, there is no consensus on a preprocedural and intraprocedural antiplatelet regimen. The aim of this single-centre study was to compare the safety and efficacy of emergency stenting in patients exhibiting intracranial atherosclerotic stenosis-related acute large-vessel occlusion with or without peri-interventional intravenous infusion of tirofiban.
We performed a retrospective analysis of 78 patients who were treated with rescuestent angioplasty between 2010 and 2019 due to acute ischaemic stroke. The patients were divided into 2 groups: those who received peri-interventional intravenous tirofiban and those who did not receive tirofiban. We compared clinical safety and functional outcomes in both treatment groups with symptomatic haemorrhage as the primary endpoint. Bivariate and multivariable logistic regression was performed to investigate the association between tirofiban and outcome measures.
Thirty-seven patients were treated with intravenous tirofiban (47.4%), and 41 patients did not receive intravenous tirofiban (52.6%). Statistical analysis revealed no significant difference between the two groups in the rate of symptomatic haemorrhage (16.2% in the tirofiban group versus 14.6% in the control group, p = 0.847). The 3-month mortality (21.6% in the tirofiban group versus 17.1% in the control group, p = 0.611) and good functional outcomes according to the modified Rankin scale (45.9% versus 34.1%, p = 0.289) were comparable.
The results of our study suggest that the application of tirofiban for rescue stenting after failed mechanical thrombectomy is safe.
对于因颅内动脉粥样硬化狭窄导致血管内血栓切除术失败的急性脑卒中患者,颅内挽救性支架血管成形术是一种挽救策略。然而,对于术前和术中的抗血小板治疗方案,目前尚未达成共识。本单中心研究旨在比较伴有或不伴有术中静脉推注替罗非班的急性颅内动脉粥样硬化性狭窄相关大血管闭塞患者行紧急支架置入术的安全性和疗效。
我们对 2010 年至 2019 年期间因急性缺血性脑卒中接受挽救性支架血管成形术的 78 例患者进行了回顾性分析。患者分为两组:术中接受替罗非班静脉推注组和未接受替罗非班静脉推注组。以症状性出血为主要终点,比较两组的临床安全性和功能结局。采用双变量和多变量逻辑回归分析替罗非班与结局指标的相关性。
37 例患者接受了替罗非班静脉推注(47.4%),41 例患者未接受替罗非班静脉推注(52.6%)。统计分析显示,两组症状性出血率无显著差异(替罗非班组 16.2%,对照组 14.6%,p=0.847)。替罗非班组 3 个月死亡率(21.6%)与对照组(17.1%)相近(p=0.611),改良 Rankin 量表评分良好的功能结局(45.9%)与对照组(34.1%)相近(p=0.289)。
本研究结果表明,机械取栓失败后应用替罗非班进行挽救性支架置入是安全的。